![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-schisandrin B | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC25A51 mRNA] | CTD | PMID:31150632 | 1,1-dichloroethene | decreases expression | ISO | RGD:1623784 | 6480464 | vinylidene chloride results in decreased expression of SLC25A51 mRNA | CTD | PMID:26682919 | 1,2-dichloroethane | decreases expression | ISO | RGD:1623784 | 6480464 | ethylene dichloride results in decreased expression of SLC25A51 mRNA | CTD | PMID:28189721, PMID:28960355 | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1623784 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of SLC25A51 mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | multiple interactions | ISO | RGD:1623784 | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SLC25A51 mRNA | CTD | PMID:22206623 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SLC25A51 mRNA | CTD | PMID:33387578 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1623784 | 6480464 | [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in decreased expression of SLC25A51 mRNA | CTD | PMID:25975270 | 3,3',4,4'-tetrachlorobiphenyl | multiple interactions | ISO | RGD:1623784 | 6480464 | 3 more ... | CTD | PMID:19467301 | 3H-1,2-dithiole-3-thione | decreases expression | EXP | | 6480464 | 1, 2-dithiol-3-thione results in decreased expression of SLC25A51 mRNA | CTD | PMID:19162173 | 4-hydroxyphenyl retinamide | increases expression | ISO | RGD:1623784 | 6480464 | Fenretinide results in increased expression of SLC25A51 mRNA | CTD | PMID:28973697 | aflatoxin B1 | increases expression | ISO | RGD:1313070 | 6480464 | Aflatoxin B1 results in increased expression of SLC25A51 mRNA | CTD | PMID:21641981 | atrazine | decreases expression | ISO | RGD:1313070 | 6480464 | Atrazine results in decreased expression of SLC25A51 mRNA | CTD | PMID:22378314 | benzo[a]pyrene | increases expression | ISO | RGD:1313070 | 6480464 | Benzo(a)pyrene results in increased expression of SLC25A51 mRNA | CTD | PMID:26238291 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of SLC25A51 mRNA | CTD | PMID:30816183 more ... | cadmium dichloride | decreases methylation | EXP | | 6480464 | Cadmium Chloride results in decreased methylation of SLC25A51 promoter | CTD | PMID:22457795 | carbamazepine | affects expression | ISO | RGD:1313070 | 6480464 | Carbamazepine affects the expression of SLC25A51 mRNA | CTD | PMID:25979313 | CGP 52608 | multiple interactions | ISO | RGD:1313070 | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to SLC25A51 gene] | CTD | PMID:28238834 | chloropicrin | increases expression | ISO | RGD:1313070 | 6480464 | chloropicrin results in increased expression of SLC25A51 mRNA | CTD | PMID:26352163, PMID:28476498 | ciguatoxin CTX1B | affects expression | ISO | RGD:1623784 | 6480464 | Ciguatoxins affects the expression of SLC25A51 mRNA | CTD | PMID:18353800 | clofibrate | decreases expression | ISO | RGD:1623784 | 6480464 | Clofibrate results in decreased expression of SLC25A51 mRNA | CTD | PMID:17585979 | copper(II) sulfate | increases expression | ISO | RGD:1313070 | 6480464 | Copper Sulfate results in increased expression of SLC25A51 mRNA | CTD | PMID:19549813 | crocidolite asbestos | decreases expression | ISO | RGD:1313070 | 6480464 | Asbestos, Crocidolite results in decreased expression of SLC25A51 mRNA | CTD | PMID:29523930 | cyclosporin A | increases expression | ISO | RGD:1313070 | 6480464 | Cyclosporine results in increased expression of SLC25A51 mRNA | CTD | PMID:25562108 | dioxygen | multiple interactions | ISO | RGD:1623784 | 6480464 | [sulforaphane affects the susceptibility to Oxygen] which affects the expression of SLC25A51 mRNA | CTD | PMID:30529165 | disodium selenite | increases expression | ISO | RGD:1313070 | 6480464 | Sodium Selenite results in increased expression of SLC25A51 mRNA | CTD | PMID:24383545 | diuron | decreases expression | EXP | | 6480464 | Diuron results in decreased expression of SLC25A51 mRNA | CTD | PMID:21551480 | dorsomorphin | multiple interactions | ISO | RGD:1313070 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A51 mRNA | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:1313070 | 6480464 | Doxorubicin results in decreased expression of SLC25A51 mRNA | CTD | PMID:29803840 | fipronil | increases expression | EXP | | 6480464 | fipronil results in increased expression of SLC25A51 mRNA | CTD | PMID:23962444 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of SLC25A51 mRNA | CTD | PMID:24136188 | folic acid | multiple interactions | ISO | RGD:1623784 | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of SLC25A51 mRNA | CTD | PMID:22206623 | folic acid | decreases expression | ISO | RGD:1313070 | 6480464 | Folic Acid results in decreased expression of SLC25A51 mRNA | CTD | PMID:21867686 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of SLC25A51 mRNA | CTD | PMID:22061828, PMID:33387578 | Heptachlor epoxide | increases expression | ISO | RGD:1623784 | 6480464 | Heptachlor Epoxide results in increased expression of SLC25A51 mRNA | CTD | PMID:25270620 | hydrogen peroxide | affects expression | ISO | RGD:1313070 | 6480464 | Hydrogen Peroxide affects the expression of SLC25A51 mRNA | CTD | PMID:21179406 | hydrogen peroxide | decreases expression | ISO | RGD:1313070 | 6480464 | Hydrogen Peroxide results in decreased expression of SLC25A51 mRNA | CTD | PMID:18951874 | hydrogen sulfide | increases expression | ISO | RGD:1623784 | 6480464 | Hydrogen Sulfide results in increased expression of SLC25A51 protein | CTD | PMID:29932956 | leflunomide | decreases expression | EXP | | 6480464 | Leflunomide results in decreased expression of SLC25A51 mRNA | CTD | PMID:24136188 | methylmercury chloride | increases expression | ISO | RGD:1313070 | 6480464 | methylmercuric chloride results in increased expression of SLC25A51 mRNA | CTD | PMID:28001369 | oxaliplatin | multiple interactions | EXP | | 6480464 | [Oxaliplatin co-treated with Topotecan] results in decreased expression of SLC25A52 mRNA | CTD | PMID:25729387 | paracetamol | increases expression | ISO | RGD:1313070 | 6480464 | Acetaminophen results in increased expression of SLC25A51 mRNA | CTD | PMID:25704631 | pentachlorophenol | increases expression | ISO | RGD:1623784 | 6480464 | Pentachlorophenol results in increased expression of SLC25A51 mRNA | CTD | PMID:23892564 | perfluorooctanoic acid | increases expression | EXP | | 6480464 | perfluorooctanoic acid results in increased expression of SLC25A51 mRNA | CTD | PMID:19162173 | phenobarbital | multiple interactions | ISO | RGD:1623784 | 6480464 | NR1I3 protein affects the reaction [Phenobarbital results in decreased expression of SLC25A51 mRNA] | CTD | PMID:19482888 | phenobarbital | increases expression | EXP | | 6480464 | Phenobarbital results in increased expression of SLC25A51 mRNA | CTD | PMID:19162173 | phenobarbital | decreases expression | ISO | RGD:1623784 | 6480464 | Phenobarbital results in decreased expression of SLC25A51 mRNA | CTD | PMID:19482888 | pirinixic acid | increases expression | ISO | RGD:1623784 | 6480464 | pirinixic acid results in increased expression of SLC25A51 mRNA | CTD | PMID:18445702 | potassium chromate | decreases expression | ISO | RGD:1313070 | 6480464 | potassium chromate(VI) results in decreased expression of SLC25A51 mRNA | CTD | PMID:22714537 | pregnenolone 16alpha-carbonitrile | increases expression | ISO | RGD:1623784 | 6480464 | Pregnenolone Carbonitrile results in increased expression of SLC25A51 mRNA | CTD | PMID:28903501 | propiconazole | increases expression | ISO | RGD:1623784 | 6480464 | propiconazole results in increased expression of SLC25A51 mRNA | CTD | PMID:21278054 | resveratrol | multiple interactions | ISO | RGD:1313070 | 6480464 | [Plant Extracts co-treated with Resveratrol] results in increased expression of SLC25A51 mRNA | CTD | PMID:23557933 | SB 431542 | multiple interactions | ISO | RGD:1313070 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A51 mRNA | CTD | PMID:27188386 | silicon dioxide | decreases expression | ISO | RGD:1623784 | 6480464 | Silicon Dioxide results in decreased expression of SLC25A51 mRNA | CTD | PMID:19073995 | sodium arsenate | decreases expression | ISO | RGD:1623784 | 6480464 | sodium arsenate results in decreased expression of SLC25A51 mRNA | CTD | PMID:30953684 | sodium dichromate | increases expression | EXP | | 6480464 | sodium bichromate results in increased expression of SLC25A51 mRNA | CTD | PMID:22561333 | sulforaphane | multiple interactions | ISO | RGD:1623784 | 6480464 | [sulforaphane affects the susceptibility to Oxygen] which affects the expression of SLC25A51 mRNA | CTD | PMID:30529165 | tamoxifen | affects expression | ISO | RGD:1623784 | 6480464 | Tamoxifen affects the expression of SLC25A51 mRNA | CTD | PMID:20937368 | temozolomide | decreases expression | ISO | RGD:1313070 | 6480464 | Temozolomide results in decreased expression of SLC25A51 mRNA | CTD | PMID:31758290 | tetrachloromethane | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC25A51 mRNA] | CTD | PMID:31150632 | tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of SLC25A51 mRNA | CTD | PMID:31150632 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of SLC25A51 mRNA | CTD | PMID:34492290 | topotecan | decreases expression | EXP | | 6480464 | Topotecan results in decreased expression of SLC25A52 mRNA | CTD | PMID:25729387 | topotecan | multiple interactions | EXP | | 6480464 | [Oxaliplatin co-treated with Topotecan] results in decreased expression of SLC25A52 mRNA | CTD | PMID:25729387 | valproic acid | increases expression | ISO | RGD:1313070 | 6480464 | Valproic Acid results in increased expression of SLC25A51 mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | RGD:1313070 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC25A51 mRNA | CTD | PMID:27188386 | valproic acid | decreases methylation | ISO | RGD:1313070 | 6480464 | Valproic Acid results in decreased methylation of SLC25A51 gene | CTD | PMID:29154799 | vinclozolin | increases methylation | EXP | | 6480464 | vinclozolin results in increased methylation of SLC25A51 gene | CTD | PMID:31682807 | zinc atom | multiple interactions | ISO | RGD:1313070 | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of SLC25A51 mRNA | CTD | PMID:18593933 | zinc(0) | multiple interactions | ISO | RGD:1313070 | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of SLC25A51 mRNA | CTD | PMID:18593933 | |